Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Apr;9(4):751-4.
doi: 10.3748/wjg.v9.i4.751.

Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C

Jian Wang  1 , Gui-Ju Xiang, Bing-Xiang Liu
Affiliations
Clinical Trial

Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C

Jian Wang et al. World J Gastroenterol. 2003 Apr.

Abstract

Aim: To study the level of membrane interleukin-2 receptor (mIL-2R) on surface of peripheral blood mononuclear cells (PBMC) and the therapeutic efficacy of alpha 2b interferon on the treatment of HCV-RNA in PBMC of patients with chronic hepatitis C and to compare the negative rates of HCV-RNA in PBMC, HCV-RNA and anti-HCV in serum.

Methods: Before and after treatment of alpha 2b interferon, the level of mIL-2R of patients with chronic hepatitis C was detected by biotin-streptavidin (BSA). The therapeutic group (26 cases) was treated with alpha 2b interferon (3 MU/d) and control therapeutic group (22 cases) was treated with routine drugs (VitC, aspartic acid). The total course of treatment with alpha 2b interferon and routine drug was six months and per course of the treatment was three months. The levels of HCV-RNA in PBMC, HCV-RNA and anti-HCV in serum were detected before and after a course of the treatment.

Results: Before and after treatment of alpha 2b interferon and routine drugs, the levels of mIL-2R in silence stage were (3.44+/-0.77) % and (2.95+/-0.72) %, the levels of mIL-2R in inducement stage were (33.62+/-3.95) % and (30.04+/-3.73) %. There was a significant difference between two groups (P<0.01-P<0.05). After treatment of alpha 2b interferon with 3 MU/d for two courses of the treatment, the total negative rates of HCV-RNA in the PBMC and HCV-RNA, anti-HCV in serum were 42.31 % (11/26), 57.69 % (15/26), 65.38 %(17/26) respectively. After the treatment of routine drug, the negative rates of HCV-RNA in PBMC and HCV-RNA, anti-HCV in serum were 13.64 % (3/22), 22.73 % (5/22), 27.27 % (6/22) respectively. There was high significant difference in the group treated with alpha 2b interferon and the group treated with routine drugs (P<0.01-P<0.05).

Conclusion: The mIL-2R can be induced by alpha 2b interferon during the treatment. The alpha 2b interferon has a definite effect on the treatment of HCV-RNA in PBMC. The curative effect of alpha 2b interferon is better than that of the routine drugs.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Piekarska A, Sidorkiewicz M, Lewandowska U, Kuydowicz J. Evaluation of persistence of IFN-alpha treatment response in chronic hepatitis C patients according with HCV-RNA presence in PBMC. Pol Arch Med Wewn. 2001;106:939–944. - PubMed
    1. Piekarska A, Kuydowicz J, Omulecka A. [Interferon alpha--treatment predictive response factors in group of adults patients with chronic hepatitis C] Pol Arch Med Wewn. 2001;106:927–937. - PubMed
    1. Patel K, McHutchison J. Peginterferon alpha-2b: a new approach to improving response in hepatitis C patients. Expert Opin Pharmacother. 2001;2:1307–1315. - PubMed
    1. Iwabuchi S, Takatsuka K. [Dynamics of serum HCV RNA levels during IFN therapy in patients with chronic hepatitis C for prediction of outcome of IFN therapy and beneficial dosing] Nihon Rinsho. 2001;59:1363–1368. - PubMed
    1. Fornai C, Maggi F, Favilli F, Vatteroni ML, Pistello M, Marchi S, Ciccorossi P, Antonelli G, Bendinelli M. Rapid changes in hepatitis C virus quasispecies produced by a single dose of IFN-alpha in chronically infected patients. J Interferon Cytokine Res. 2001;21:417–422. - PubMed

Publication types